Kow Chia Siang

Kow Chia Siang

  • Senior Lecturer
  • School of Pharmacy
Faculty of Medical and Life Sciences
SDGs Focus

Biography

Kow Chia Siang is an internationally recognized researcher, ranked among the world’s top 2% of scientists in the field of Pharmacy and Pharmacology by the prestigious Stanford University list. His research spans clinical outcomes, systematic reviews, and meta-analyses across cardiometabolic, infectious disease, and pharmacotherapy domains, with numerous publications in high-impact journals. He has made significant contributions to advancing evidence-based practice through rigorous methodology, innovative analyses, and global collaborations. His work not only strengthens the scientific evidence base but also informs clinical guidelines and healthcare policies.

Academic & Professional Qualifications

  • Bachelor in Pharmacy (Hons), IMU University, Malaysia (2017)
  • Master in Pharmacy Practice, IMU University, Malaysia (2021)

Research Interests

  • Evidence-based medicine
  • Pharmacy practice
  • Clinical pharmacy
  • Clinical pharmacology

Teaching Areas

  • Evidence-based medicine
  • Pharmacy practice
  • Pharmacology

Notable Publications

  1. Kow CS, Zaidi STR, Hasan SS. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. Am J Cardiovasc Drugs. 2020;20(3):217-221. doi:10.1007/s40256-020-00406-0
  2. Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. Am J Cardiovasc Drugs. 2020;20(4):301-309. doi:10.1007/s40256-020-00415-z
  3. Kow CS, Thiruchelvam K, Hasan SS. Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. Expert Rev Cardiovasc Ther. 2020;18(8):475-485. doi:10.1080/14779072.2020.1797492
  4. Kow CS, Capstick T, Zaidi STR, Hasan SS. Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients. Eur J Hosp Pharm. 2021;28(1):42-46. doi:10.1136/ejhpharm-2020-002388
  5. Kow CS, Doi SAR, Hasan SS. The coincidence of increased risk of atrial fibrillation in randomized control trials of omega-3 fatty acids: a meta-analysis. Expert Rev Clin Pharmacol. 2021;14(6):773-775. doi:10.1080/17512433.2021.1913051
  6. Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Spironolactone for the Treatment of Moderate to Severe Acne in Adult Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Australas J Dermatol. 2025;66(3):165-168. doi:10.1111/ajd.14428
  7. Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials. Sleep Med. 2025;129:40-44. doi:10.1016/j.sleep.2025.02.010
  8. Kow CS, Ramachandram DS, Hasan SS, Wong Z, Thiruchelvam K. The efficacy of pentoxifylline for major depressive disorder : A systematic review and meta-analysis of randomized controlled trials. Wien Klin Wochenschr. Published online March 26, 2025. doi:10.1007/s00508-025-02519-5
  9. Kow CS, Chen F, Jie Leong SK, et al. Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications. Expert Rev Cardiovasc Ther. 2025;23(6):303-315. doi:10.1080/14779072.2025.2523920
  10. Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. Published online July 29, 2025. doi:10.1007/s10787-025-01876-x
     

Achievements & Accolades

  1. Ranked among the world’s top 2% of scientists in Pharmacy and Pharmacology according to the prestigious Stanford University global database in 2022-2024
  2. Malaysia’s Research Star Award 2025